Researchers discuss HER2-low and HER2-zero in breast cancer
A new editorial paper titled "HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity" has been published in Oncotarget.
Jul 16, 2024
0
38
Amino Acids, Peptides, and Proteins: News and Research on Trastuzumab
MeSH tree: D12.776.124.486.485.114.224.060.875
New model could reduce reliance on chemotherapy
A model co-designed by a professor at Anglia Ruskin University is expected to reduce the need for chemotherapy in up to 38% of breast cancer patients who would previously have been advised to consider the treatment.
Jul 12, 2024
0
47
Antibody-drug conjugate highly effective in preventing recurrence in early stage HER2+ breast cancer, trial finds
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute ...
Jun 27, 2024
0
50
Combination therapy shows promise in subset of breast cancers
Combining two cancer drugs may be a promising treatment for advanced metastatic breast cancer, according to the results of a clinical trial published in JAMA Oncology.
Jun 17, 2024
0
58
New platform streamlines epitope comparison in antibody research
Monoclonal antibodies are crucial therapeutics due to their high specificity and binding affinity for epitopes (the precise sites where an antibody attaches itself to an antigen, triggering an immune response). Since the ...
Jun 10, 2024
0
26
Drug resistance discovery could 'move the field forward' for breast cancer treatment
Research recently published in Drug Resistance Updates has revealed a previously unknown biological process through which breast tumor cells develop resistance to standard treatment, which could open the door for cancer scientists ...
May 29, 2024
0
44
Understanding what causes trastuzumab's cardiotoxicity
A new meta-analysis published in OMICS: A Journal of Integrative Biology helps shed light on how changes in mitochondria-related gene expression may cause the cardiotoxicity associated with the cancer therapy trastuzumab.
Mar 18, 2024
0
44
A breast cancer drug, susceptible to resistance, can be restored to effectiveness, researchers demonstrate
In a new paper published in Cancer Research, researchers at MUSC Hollings Cancer Center have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can restore the effectiveness ...
Feb 6, 2024
0
41
Mathematical model mimics vascular tumor growth in breast cancer and its response to treatment
Choosing the right cancer treatment is a massive undertaking involving multiple stages, high experimental complexity and significant costs. Currently, two main methods are used to find the best possible treatment solutions: ...
Jan 16, 2024
0
20
Tucatinib plus trastuzumab emtansine may benefit patients with advanced or metastatic HER2-positive breast cancer
A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast ...
Dec 6, 2023
0
34
